BIOCELTIX S.A. ZY -10

Research BIOCELTIX S.A. ZY -10 (XI3) on Bullrun: market cap EUR 94.82M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerXI3
• ExchangeF
• CountryPoland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 94.82M
• Financial periodQ3 2025
• Net income-EUR 4.38M
• Free cash flow-EUR 5.83M

Valuation Snapshot

latest market cap is EUR 94.82M.

About BIOCELTIX S.A. ZY -10

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wroclaw, Poland.

Frequently asked questions

What is BIOCELTIX S.A. ZY -10's market cap?

BIOCELTIX S.A. ZY -10's market capitalization is EUR 94.82M.

What does BIOCELTIX S.A. ZY -10 do?

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs;